文献速递主动脉外科

新型主动脉弓杂交假体修复急性DeBakey I型夹层伴灌注不良的1年结果:PERSEVERE研究

One-Year Results of Novel Aortic Arch Hybrid Prosthesis for Repair of Acute DeBakey Type I Dissection With Malperfusion: PERSEVERE Study.
PubMed 文献 · Ann Thorac Surg · 2025-11-12

PERSEVERE是一项前瞻性单臂多中心研究,评估AMDS杂交假体治疗急性DeBakey I型主动脉夹层伴灌注不良患者的1年结局。93例入组患者中,1年内死亡19例(20%),新发致残性卒中11例(12%),需透析的肾衰竭19例(20%),心肌梗死2例(2%),多数事件发生在30天内;术后CT血管造影未记录到远端吻合口新发破口(DANE),主动脉再手术免除率为96%,弓部血管通畅率为100%,并观察到积极的主动脉重塑证据。

要点

  • AMDS杂交假体1年死亡率20%,主要不良事件多集中在术后30天内。
  • 术后CT未发现远端吻合口新发破口(DANE),再手术免除率96%。
  • 1年主动脉重塑积极,zone 1-3假腔血栓形成率分别为91%、92%、88%。

核心结论

  • AMDS杂交假体1年结局令人鼓舞,死亡率低于既往观察,30天后主要事件有限,且无DANE记录,并有积极的主动脉重塑证据。

研究设计与样本

  • PERSEVERE为前瞻性单臂多中心临床研究(NCT05174767),评估AMDS杂交假体治疗急性DeBakey I型夹层伴灌注不良的安全性和有效性。
  • 共入组93例患者,63例(68%)完成1年随访,56例有CT血管造影资料。

主要发现

  • 1年内死亡19例(20%),新发致残性卒中11例(12%),需透析19例(20%),心肌梗死2例(2%),多数事件发生在30天内。
  • 术后CT血管造影未记录到远端吻合口新发破口(DANE)。
  • 免于非预期主动脉再手术率为96%(89/93),弓部血管通畅率为100%(91/91)。
  • 1年免于主动脉总增长率在zone 1为100%,zone 2为98.2%,zone 3为73.2%。
  • zone 1至3的真腔扩张率分别为96%、94%、70%,假腔血栓形成率分别为91%、92%、88%。

临床怎么用

  • 对于急性DeBakey I型夹层伴灌注不良患者,AMDS杂交假体可作为半弓修复的替代选择,术后30天内需密切监测主要不良事件。
  • 术后影像随访应关注主动脉重塑指标,包括真腔扩张、假腔血栓形成及zone 3的主动脉增长。

局限性

  • 单臂设计缺乏对照组,1年随访完成率68%,可能存在选择偏倚和信息偏倚。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: High rates of major adverse events and negative aortic remodeling are common after hemiarch repair for acute DeBakey type I aortic dissection. The ProspEctive, Single ARm, Multi-center Clinical InveStigation to EValuatE the Safety and Effectiveness of AMDS in the TREatment of Acute DeBakey Type I Dissection (PERSEVERE; NCT05174767) study evaluated 1-year outcomes with the AMDS Hybrid Prosthesis i(Artivion, Inc) n patients with malperfusion. METHODS: PERSEVERE is a prospective, single arm study. Primary end point events of mortality, new disabling stroke, new renal failure requiring dialysis, myocardial infarction, and rate of distal anastomotic new entry (DANE) tears were assessed through 1 year. Reoperation, aortic patency, and changes in aortic remodeling, including total aortic growth, true lumen expansion, and false lumen thrombosis, were also reported. RESULTS: Of 93 enrolled patients, 63 (68%) completed 1-year follow-up, and 56 patients had a computed tomographic angiogram. Through 1 year, 19 (20%) patients died, 11 (12%) had new disabling strokes, 19 (20%) required dialysis, and 2 (2%) had a myocardial infarction; most events Occurred within 30 days. DANE was not documented in any postoperative computed tomographic angiograms. Freedom from unanticipated aortic reoperations and occlusion in the arch was 96% (89 of 93) and 100% (91 of 91), respectively. Freedom from total aortic growth at 1 year was 100% in zone 1, 98.2% in zone 2, and 73.2% in zone 3. In zones 1 to 3, true lumen expansion occurred in 96%, 94%, and 70% of patients, respectively. In zones 1 to 3, false lumen thrombosis occurred in 91%, 92%, and 88% of patients, respectively. CONCLUSIONS: The 1-year outcomes with the AMDS Hybrid Prosthesis are encouraging, with lower than observed mortality, limited primary events after 30 days, and the absence of DANE. There is evidence of positive aortic remodeling. Follow-up is ongoing.

来源:Ann Thorac Surg,查看原文。版权归原作者所有。

引用

  1. Szeto WY, Fukuhara S, Fleischman F, et al. One-Year Results of Novel Aortic Arch Hybrid Prosthesis for Repair of Acute DeBakey Type I Dissection With Malperfusion: PERSEVERE Study. Ann Thorac Surg. 2025. PMID: 41238072. doi:10.1016/j.athoracsur.2025.10.036

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。